Curcumin: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Curcumin |FDA_approval=No (Used as a dietary supplement; not FDA-approved for cancer treatment) |used_for=Investigational use in cancer treatment and prevention; also used for symptom management like dermatitis from radiotherapy |clinical_trial_phase=Preclinical studies and early clinical trials |common_side_effects=Generally well-tolerated; bioavailability issues are noted, but can be improved with piperine |OS_with=Not applicable; studies foc...") |
No edit summary |
||
| Line 8: | Line 8: | ||
|PFS_with=Not applicable; research has not extensively measured progression-free survival in cancer patients | |PFS_with=Not applicable; research has not extensively measured progression-free survival in cancer patients | ||
|usefulness_rating=3 | |usefulness_rating=3 | ||
|toxicity_level=1 | |||
|notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment. | |notes=Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment. | ||
|category=Nutraceuticals and Herbals | |category=Nutraceuticals and Herbals | ||
|original_text=Curcumin | |||
This is an ingredient in the Indian cooking spice, turmeric. It has been shown to inhibit | |||
the growth of cancer cells of various types in laboratory studies via numerous different | |||
mechanisms (272). Like genistein, it inhibits the tyrosine kinase signaling and also | |||
inhibits angiogenesis. Perhaps most importantly, it inhibits proteins that prevent | |||
damaged cells from undergoing apoptosis, a family of genes known as nuclear factor | |||
kappa B. Of all of the supplements on this list it is the most potent anti-cancer agent in | |||
laboratory studies. However, it also should be noted that its bioavailability from oral | |||
intake is limited, although bioavailability supposedly is increased when curcumin is | |||
combined with piperine (the main ingredient in black pepper). The Life Extension | |||
Foundation sells a version of curcumin that they claim has much greater bioavailability | |||
than anything else on the market. Despite the limited bioavailability, there is some | |||
evidence of clinical effectiveness. In a study of dermatitis induced by radiotherapy for | |||
breast cancer, a double-blind placebo controlled trial compared a placebo with curcumin | |||
(2 grams three times/day), both of which were taken throughout radiation treatment. | |||
Significantly less dermatitis occurred in patients receiving curcumin (273). | |||
Curcumin has also been used in combination with a second supplement, quercetin, (see | |||
below) for the treatment of an inherited disorder of the colon in which hundreds of | |||
adenomas develop and eventually colon cancer (274). Five patients with the disorder | |||
received 480 mg of curcumin and 20 mg of Quercetin three times daily. Polyp number | |||
and size were assessed at baseline and then six months after starting the supplements. | |||
For all patients there was a decrease in polyp size and number, which was statistically | |||
significant. | |||
|links= | |links= | ||
}} | }} | ||
Revision as of 00:08, 26 March 2024
| Property | Information |
|---|---|
| Drug Name | Curcumin |
| FDA Approval | No (Used as a dietary supplement; not FDA-approved for cancer treatment) |
| Used for | Investigational use in cancer treatment and prevention; also used for symptom management like dermatitis from radiotherapy |
| Clinical Trial Phase | Preclinical studies and early clinical trials |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Generally well-tolerated; bioavailability issues are noted, but can be improved with piperine |
| OS without | Not specified |
| OS with | Not applicable; studies focus on cellular and symptom management rather than direct survival outcomes |
| PFS without | Not specified |
| PFS with | Not applicable; research has not extensively measured progression-free survival in cancer patients |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 1 |
| Toxicity Explanation | Not specified |
Notes: Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.
From Ben Williams Book: Not specified
Loading comments...
